Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Traws Pharma, Inc.

NASDAQ: TRAW · Life Sciences · 3 alerts · CIK 1130598

Share price
$0.2600Close, Nov 16
Market cap
$4M
Shares outstanding
15.37MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Traws Pharma, Inc. filings on SEC EDGAR ↗

4:46 PM ET 8-K
Financial Results

Traws Pharma Financial Results

Traws Pharma reported Q3 2026 financial results and provided clinical updates for its COVID-19 and influenza antiviral programs. The company highlighted positive Phase 2a results for ratutrelvir and plans to engage the FDA on a registration strategy for PAXLOVID-ineligible patients.

Term
Q3 2026

“We have made meaningful progress toward our goal of developing new treatment and prevention options for patients most vulnerable to serious respiratory viral diseases.”

Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma

“For tivoxavir marboxil, the tablet bridging study achieved its objectives, and toxicology retesting is complete. These results support further evaluation of TXM as a potential once-monthly oral influenza prevention option. We expect to resubmit the updated toxicology package in the fourth quarter.”

Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma
7:01 AM ET 8-K
Clinical Trial Data

Traws Pharma Clinical Trial Data

Traws Pharma announced final Phase 2a results for Ratutrelvir, showing symptom resolution comparable to PAXLOVID with no viral rebound and fewer treatment-related adverse events in COVID-19 patients. The company also completed a bridging study for Tivoxavir Marboxil (TXM), supporting its potential as a once-monthly influenza prophylactic agent.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.